Skip to content
drillr.ai
Sign up

PPCB

Propanc Biopharma, Inc.

NASDAQ · Healthcare · Biotechnology · AU

$1.80
+5.26%
Ask drillr

  • Nov 2, 2026, 13:30 UTC

    Propanc Biopharma filed an Australian patent application relating to combining its pancreatic proenzyme formulation with galunisertib.

    Source:

  • Oct 29, 2026, 21:59 UTC

    Propanc Biopharma said it received a NASDAQ, INC. notice concerning noncompliance with the minimum bid price requirement and intends to request an appeal by October 30, 2026.

  • Oct 28, 2026, 12:30 UTC

    Propanc Biopharma, Inc. advanced preparations for a planned PRP Phase 1b first-in-human study involving up to 50 patients with advanced cancer.

    Source:

  • Oct 16, 2026, 12:36 UTC

    Propanc Biopharma announced new preclinical research identifying its pancreatic proenzyme formulation PRP as a potential strategy for addressing chemotherapy resistance in pancreatic cancer.

    Source:

  • Oct 14, 2026, 12:30 UTC

    Propanc Biopharma announced publication of a peer-reviewed pilot study evaluating its PRP pancreatic proenzyme formulation in pancreatic and ovarian cancer.

    Source:

  • Sep 9, 2026, 12:30 UTC

    Propanc Biopharma announced plans to commence a world-first Phase 1b first-in-human study of its drug candidate PRP in February 2027.

    Source:

  • Aug 18, 2026, 12:30 UTC

    Propanc Biopharma announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human Phase 1b clinical study of PRP in up to 40 advanced cancer patients with solid tumors.

    Source:

  • Aug 6, 2026, 12:30 UTC

    Propanc Biopharma announced positive preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma models, showing over 90% tumor growth inhibition and significant survival benefit.

    Source:

  • Aug 5, 2026, 12:30 UTC

    Propanc Biopharma announced the completion of the first tranche of $500,000 of its $5.0 million share repurchase program within the first 30 days since commencing the program.

    Source:

  • Jul 7, 2026, 12:30 UTC

    Propanc Biopharma signed a Memorandum of Understanding with Avance Clinical Pty Ltd to collaborate on the clinical delivery of Propanc's Phase 1b trial for PRP.

    Source:

  • Jun 11, 2026, 12:30 UTC

    Propanc Biopharma authorized a share repurchase program of up to $5.0 million of its common stock.

    Source: